BMC Cancer最新文献

{"title":"Toll-like receptor 9 (TLR9) expression correlates with cell of origin and predicts clinical outcome in diffuse large B-cell lymphoma.","authors":"Sulaf Abd Own, Ioanna Xagoraris, Konstantina Stathopoulou, Björn E Wahlin, Weicheng Ren, Mehran Ghaderi, Qiang Pan-Hammarström, Birgitta Sander, Karin E Smedby, Georgios Rassidakis","doi":"10.1186/s12885-025-14359-7","DOIUrl":"10.1186/s12885-025-14359-7","url":null,"abstract":"<p><strong>Background: </strong>Biological insights beyond the cell-of-origin (COO) classification can support clinical management in diffuse large B-cell lymphoma (DLBCL). We investigated if Toll-like receptor 9 (TLR9) expression could serve as a prognostic marker in DLBCL.</p><p><strong>Method: </strong>TLR9 gene expression was analysed in four publicly available cohorts (n = 2474), and protein expression was investigated in germinal centre B-cell (GCB) and activated B-cell (ABC) DLBCL cell lines. Next, TLR9 protein expression was analysed in 120 diagnostic samples from R-CHOP-treated patients with relapsed/refractory disease (poor outcome, n = 50) or in complete remission (good outcome, n = 70). Associations were evaluated using logistic regression, estimating odds ratios (OR) and 95% confidence intervals (CI).</p><p><strong>Results: </strong>TLR9 gene expression was higher in ABC DLBCL compared to GCB DLBCL in external cohorts, and similar results were obtained for protein expression in cell lines. In patient samples, high TLR9 protein expression correlated with non-GCB type (p = 0.003) and poor outcome (p = 0.0016). High TLR9 expression remained associated with poor outcome in multivariable analysis after adjusting for COO and other clinical features (OR = 3.36, 95% CI 1.41-8.04). In exploratory analyses, a decrease of cell growth in ABC cell lines following inhibition of TLR9 activity with ODN4084-F was suggested.</p><p><strong>Conclusion: </strong>We conclude that TLR9 correlates with ABC/non-GCB phenotype and is a potential predictor of poor prognosis in DLBCL.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"959"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.","authors":"Hao Meng, Ren-Quan Ding, Lei Jia, Xiang-Peng Chen, Yu-Hang Hu, Shu-Min Wang, Si-Qi Lv, Fan Feng","doi":"10.1186/s12885-025-14386-4","DOIUrl":"10.1186/s12885-025-14386-4","url":null,"abstract":"<p><p>Porphyrins, as drug-food homologous bioactive substances, hold significant potential in nanomedicine research and photodynamic therapy (PDT). In this study, we synthesized two novel porphyrin compounds, PTA and PTBA, based on the porphyrin compound TCPP. Using these compounds, we prepared metal-porphyrin nanoparticles and evaluated their properties. Results from multiple assays demonstrated that both PTA and PTBA exhibited significantly enhanced photodynamic therapeutic activation under laser irradiation compared to TCPP. This included improved reactive oxygen species (ROS) and singlet oxygen release, as well as superior antitumor activity. When prepared as metal-porphyrin nanoparticles, all three compounds-PCN224 (TCPP with Zr⁴⁺), PMOF01 (PTA with Zr⁴⁺), and PMOF02 (PTBA with Zr⁴⁺)-showed significantly upregulated photodynamic therapeutic effects. These nanoparticles induced the accumulation of ROS and singlet oxygen in lung squamous cell carcinoma (LSCC) cells and demonstrated both in vitro and in vivo antitumor activity under laser irradiation. Notably, PMOF01 and PMOF02 exhibited much stronger antitumor effects compared to PCN224 in LSCC cells. Our findings highlight the photodynamic therapeutic potential of these novel porphyrin compounds and their nanoparticles. These results not only expand our understanding of porphyrins' antitumor capabilities but also provide new options for PDT applications.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"960"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-frequency contrast-enhanced ultrasound in discriminating benign and malignant superficial lymph nodes: a diagnostic comparison.","authors":"Shuyuan Liang, Peng Han, Xiang Fei, Lianhua Zhu, Liuqing Peng, Fang Xie, Yukun Luo","doi":"10.1186/s12885-025-14238-1","DOIUrl":"10.1186/s12885-025-14238-1","url":null,"abstract":"<p><strong>Background: </strong>Lymph nodes are critical immune system components, filtering harmful substances and acting as indicators in various disease states, including cancer. Accurate differentiation between benign and malignant superficial lymph nodes is essential for diagnosis and treatment planning. However, conventional diagnostic methods often lack the required precision. High-frequency contrast-enhanced ultrasound (H-CEUS) offers improved temporal resolution and visualization of microvascular structures, potentially providing better diagnostic accuracy than standard contrast-enhanced ultrasound (CEUS).</p><p><strong>Methods: </strong>This study included 77 patients with suspected abnormalities in superficial lymph nodes. Each patient underwent H-CEUS and CEUS examinations, with diagnoses confirmed through biopsy or surgical resection. The diagnostic performance of H-CEUS and CEUS was evaluated using sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. Chi-square tests and ROC curve analysis were employed to compare the efficacy of H-CEUS and CEUS in differentiating benign from malignant lymph nodes.</p><p><strong>Results: </strong>H-CEUS demonstrated superior diagnostic performance over CEUS, with higher sensitivity (95.92% vs. 83.67%), specificity (92.86% vs. 57.14%), and accuracy (94.80% vs. 74.03%). H-CEUS enhanced microvascular morphology visualization, facilitating more accurate differentiation between benign and metastatic lymph nodes. The area under the ROC curve for H-CEUS (0.944) was significantly greater than that for CEUS (0.704), indicating improved diagnostic capability.</p><p><strong>Conclusion: </strong>H-CEUS offers enhanced accuracy in diagnosing the nature of superficial lymph nodes, potentially improving clinical decision-making for patients with suspected lymph node malignancies. These findings support the integration of H-CEUS into routine clinical practice to achieve better diagnostic outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"961"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in patients with metastatic colorectal cancer receiving cytotoxic and cytotoxic plus targeted therapy.","authors":"Hong Tham Pham, Tuan Anh Nguyen, Thao Le Ba, Vo Ngoc Minh Tran, Ronald L Castelino, Kim-Huong Truong-Nguyen, Bao Khanh Nguyen, Megan K Fischer, Viet Dung Tran, Minh-Hoang Tran","doi":"10.1186/s12885-025-14388-2","DOIUrl":"10.1186/s12885-025-14388-2","url":null,"abstract":"<p><strong>Background: </strong>Targeted therapies in the treatment of metastatic colorectal cancer (mCRC) have reportedly been associated with better quality of life (QoL). Previous studies have revealed uncontrolled sources of biases or confounders that could distort this association. Given the lack of robust evidence and causal inference, we aimed to investigate the effects of targeted therapy-added regimens versus cytotoxic therapy (CyT) on QoL and components of QoL in patients with mCRC eligible for curative-intent treatment.</p><p><strong>Methods: </strong>We conducted a prospective cohort study on adults undergoing curative-intent mCRC treatment with survival prognosis of ≥ 1 year. The exposure was either CyT alone (including CAPEOX, mFOLFOX-6, mFOLFOX-7, FOLFIRI, and FOLFOXIRI) or CyT combined with targeted therapy (Cy-TaT, including CAPEOX-TaT, mFOLFOX-6-TaT, mFOLFOX-7-TaT, FOLFIRI-TaT, and FOLFOXIRI-TaT). Available targeted therapies included bevacizumab and regorafenib. The primary outcome was overall health and QoL (H/QoL), measured at month 12 using the EORTC QLQ-C30 global health status/QoL scale (in percentage point) and the EQ-5D-3L utility score. The secondary outcomes included each component of the EORTC QLQ-C30 functional scales and symptom scales/items (in percentage point), measured at month 12. Mean difference (MD) and 95% confidence interval (95% CI) were estimated using g-estimation.</p><p><strong>Results: </strong>During 12 months of follow-up, among 1143 participants (mean age 58.1, 39.4% being female, 623 in CyT group and 520 in Cy-TaT group), overall H/QoL was higher in those receiving Cy-TaT (EORTC QLQ-C30 global health status/QoL scale: MD 16.6, 95% CI 14.8 to 18.4, p < 0.001 [largest effect in CAPEOX-TaT versus CAPEOX: MD 18.7, 95% CI 15.2 to 22.2]; EQ-5D-3L utility score: MD 0.076, 95% CI 0.060 to 0.091 [largest effect in mFOLFOX-7-TaT versus mFOLFOX-7: MD 0.123, 95% CI 0.085 to 0.161]). For the EORTC QLQ-C30 functional scales and most areas of the symptom scales/items, treatment with Cy-TaT was also associated with better outcomes than with CyT, except for a contradictory association in financial difficulties. Symptoms with consistently large improvements from Cy-TaT were fatigue (MD 13.8, 95% CI 11.7 to 15.9), dyspnoea (MD 10.9, 95% CI 8.8 to 12.9), and insomnia (MD 13.0, 95% CI 10.2 to 15.7).</p><p><strong>Conclusion: </strong>Compared with those on CyT alone, patients with mCRC receiving Cy-TaT showed improved overall H/QoL, functional scales, and symptom scales/items. These benefits were consistent across most subgroups of chemotherapy, with the greatest improvements in H/QoL observed in the CAPEOX-TaT and mFOLFOX-7-TaT groups.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"957"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells.","authors":"Pengwei Qi, Jingting Zhao, Hongtian Zhang, Xingyu Liu, Qing You, Jianguo Niu, Xiangming Ye, Fangfang Li","doi":"10.1186/s12885-025-14333-3","DOIUrl":"10.1186/s12885-025-14333-3","url":null,"abstract":"<p><strong>Background: </strong>Actin remodeling plays important roles in pathophysiological processes such as cancer metastasis and angiogenesis. Reactive oxygen species (ROS) are signaling molecules thought to regulate cell migration by remodeling actin cytoskeleton. Earlier, we demonstrated that Transient receptor potential melastatin 2 (TRPM2) channels mediates H₂O₂-induced actin remodeling and cell migration in HeLa cells by manipulating Ca²⁺ and Zn²⁺. However, the mechanism by which ROS produced in models more relevant to pathophysiological circumstances affect the actin cytoskeleton, remains poorly unknown. Therefore, this study aimed to explore the effect of ROS produced from pathophysiological conditions on actin cytoskeleton and cell migration. And then investigates the role of TRPM2 channels in the regulation of these types of ROS-induced actin remodeling and cell migration in prostate cancer cells.</p><p><strong>Methods: </strong>The study utilized various molecular probes, reagents, and cell culture techniques. Prostate cancer (PC)-3 and DU145 cell line were cultured and treated with different compounds to induce ROS production and actin remodeling. The actin cytoskeleton was stained with phalloidin or labelled with pActin-tdTomato plasmid and imaged using confocal microscopy. Zn²⁺ and Ca²⁺ levels were measured by Fluozin3-AM and Fluo4-AM probes respectively. Cell migration as-says were performed to assess the role of TRPM2 channels.</p><p><strong>Results: </strong>We demonstrated that both H₂O₂ and palmitate induces TRPM2-dependent elevation of cytosolic Ca²⁺ and Zn²⁺, leading to actin remodeling both in PC-3 and DU145 cells. Inhibition or knockdown of TRPM2 channels or chelation of Zn²⁺ significantly reduced these effects.</p><p><strong>Conclusions: </strong>TRPM2 channels and TRPM2-mediated Zn²⁺ are essential in ROS-induced actin remodeling and cell migration in prostate cancer cells. Preventing TRPM2 channel activation and chelating Zn²⁺ may offer potential therapeutic strategies for preventing cancer metastasis. Further research is needed to identify molecular targets of Zn²⁺ in the actin cytoskeleton and cancer cell migration.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"956"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten-year follow-up of atypical small acinar hyperplasia cases diagnosed by initial prostate biopsy.","authors":"Rui Su, Shi-Jie Ye, Su-Ying Wang, Zhou-Liang Zhang, Hui-Ping Chen, Hui-Zhi Zhang, Chang Li, Ming Zhao, Xin Fei, Ze-Jun Yan, Qi Ma","doi":"10.1186/s12885-025-14366-8","DOIUrl":"10.1186/s12885-025-14366-8","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical outcomes and diagnostic strategies for patients with atypical small acinar hyperplasia (ASAP) in their initial prostate biopsy in a real-world setting.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the data of 170 patients who received their first prostate biopsy result as ASAP. The lost follow-up rate, clinical interventions, subsequent pathological results, prostate cancer detection rate, and Gleason scores were analyzed. Furthermore, subgroup analysis was performed on cases with repeat biopsies.</p><p><strong>Results: </strong>Of the 170 patients, 45 were lost to follow-up, with a dropout rate of 26.5%. Among the remaining 125 patients, 68 did not receive clinical intervention. Meanwhile, 57 underwent clinical interventions during follow-up, including 50 with repeat biopsies (50 second-time biopsies, 8 third-time biopsies, and 2 fourth-time biopsies), 3 underwent transurethral resection of prostate (TURP), and 4 had radical surgeries. In total, 28 were diagnosed with prostate cancer, diagnoses included 22 cases from prostate biopsies, 2 from TURP, and 4 from radical surgeries. Of the 22 biopsy-confirmed prostate cancer cases, 17 underwent radical surgeries at our hospital. Postoperative pathology revealed that 71.4%(5/7) of the cases upgraded from clinically insignificant cancer to clinically significant cancer. Ultimately, clinically significant prostate cancer accounted for 85.7%(24/28) of all positive cases and 42.1%(24/57) of the clinically intervened cases. Further subgroup analysis revealed that biopsy groups 6-12 months post-initial ASAP diagnosis had a noticeably higher positive rate than those biopsied within 6 months.</p><p><strong>Conclusion: </strong>For the patients with ASAP diagnosed by the initial biopsy, the risk of subsequent diagnosis of clinically significant prostate cancer is high. Combined with the high dropout rate and postoperative pathological escalation rate in this study cohort, it is recommended that patients with ASAP be given high priority in clinical practice, and repeated biopsy is recommended to be carried out within 6-12 months.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"964"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating SEResNet101 and SE-VGG19 for advanced cervical lesion detection: a step forward in precision oncology.","authors":"Yan Ye, Yuanyuan Chen, Jiajia Pan, Peipei Li, Feifei Ni, Haizhen He","doi":"10.1186/s12885-025-14353-z","DOIUrl":"10.1186/s12885-025-14353-z","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer remains a significant global health issue, with accurate differentiation between low-grade (LSIL) and high-grade squamous intraepithelial lesions (HSIL) crucial for effective screening and management. Current methods, such as Pap smears and HPV testing, often fall short in sensitivity and specificity. Deep learning models hold the potential to enhance the accuracy of cervical cancer screening but require thorough evaluation to ascertain their practical utility.</p><p><strong>Methods: </strong>This study compares the performance of two advanced deep learning models, SEResNet101 and SE-VGG19, in classifying cervical lesions using a dataset of 3,305 high-quality colposcopy images. We assessed the models based on their accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>The SEResNet101 model demonstrated superior performance over SE-VGG19 across all evaluated metrics. Specifically, SEResNet101 achieved a sensitivity of 95%, a specificity of 97%, and an AUC of 0.98, compared to 89% sensitivity, 93% specificity, and an AUC of 0.94 for SE-VGG19. These findings suggest that SEResNet101 could significantly reduce both over- and under-treatment rates by enhancing diagnostic precision.</p><p><strong>Conclusion: </strong>Our results indicate that SEResNet101 offers a promising enhancement over existing screening methods, integrating advanced deep learning algorithms to significantly improve the precision of cervical lesion classification. This study advocates for the inclusion of SEResNet101 in clinical workflows to enhance cervical cancer screening protocols, thereby improving patient outcomes. Future work should focus on multicentric trials to validate these findings and facilitate widespread clinical adoption.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"963"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world.","authors":"Changsong Wang, JingChang Chen, Xuexia Lv, Tian Yun, Yaxi Wang, Nianlong Meng, Fulin Li, Yansha Cao, Naijun Fan, Xiaoyue Wang","doi":"10.1186/s12885-025-14374-8","DOIUrl":"10.1186/s12885-025-14374-8","url":null,"abstract":"<p><p>The Ki-67 index, which is a proliferative index, has become more important in making treatment decisions for patients with breast cancer (BC) and plays both a predictive role and a prognostic role. However, a few factors limit its use in clinical practice, particularly the assessment of the percentage of Ki-67-positive cells and the cutoff value of Ki-67. In this study, we examined the expression of Ki-67 via immunohistochemistry and systematically evaluated the value of the Ki-67 index in patients with BC. This was a retrospective study including 280 patients diagnosed with BC. There were marked differences in overall survival (OS) between patients with BC when the Ki-67 index ranged from 46 to 68% (χ2 = 5.87, P = 0.0154; χ2 = 7.64, P = 0.0057, respectively), and the same results were also found when the staining density was added to the Ki-67 index; however, the staining density alone has limited value in assessing the value of Ki-67. There were marked differences in disease-free survival (DFS) among BC patients when the Ki-67 index ranged from 50 to 58% (χ2 = 7.31, P = 0.0069; χ2 = 7.88, P = 0.005). When 14% was used as a cutoff point to classify the molecular type of BC, the luminal A-type patients were significantly different from patients with HER2-overexpressing subtype BC in terms of OS (χ2 = 5.33, P = 0.021). There was a significant difference in the OS of patients with human epidermal growth factor receptor 2 (HER-2)-overexpressing subtype BC when the Ki-67 index fell within the range of 49-60% (χ2 = 4.86, P = 0.0275; χ2 = 5.50, P = 0.019, respectively). There were significant differences between luminal A-type BC and HER2-overexpressing subtype BC in terms of OS (χ2 = 5.53, P = 0.019), according to suggestions of the 2019 CSCO consensus. There were significant differences between the two groups of luminal B HER-2(-) BC when the Ki-67 index was 52% (χ2 = 6.61, P = 0.0101). The differentiated Ki-67 index can be used to assess the OS and DFS of patients with BC, and the staining density of Ki-67 has little value in assessing prognosis in these patients. Different molecular classification methods may influence the assessment of prognosis and the results of molecular subtype in patients with BC. To predict the prognosis of BC patients, it is more scientifically feasible to use the interval values of Ki-67 than a specific value.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"962"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers and opportunities related to access to oncology care in Benin: a qualitative study on breast cancer.","authors":"Clémence Schantz, Freddy Houéhanou Rodrigue Gnangnon, Moufalilou Aboubakar, Anthelme Kouessi Agbodande, Paloma Puig, Justin Lewis Denakpo, Angéline Tonato Bagnan, Marie Bottin, Komi Mena Agbodjavou, Hélène Robin Sacca, Luis Teixeira, Valéry Ridde","doi":"10.1186/s12885-025-14325-3","DOIUrl":"https://doi.org/10.1186/s12885-025-14325-3","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most prevalent cancer among women globally, including in Africa. Oncology is a relatively new discipline in many West African countries, particularly in Benin. There is currently a lack of data concerning the current state of cancer care infrastructure and oncology practices within these countries. The aim of the article is to describe the barriers and opportunities related to access to oncology care in Benin.</p><p><strong>Methods: </strong>We employed a qualitative research design. Fifty-six semi-structured interviews were conducted with caregivers treating cancer (n=26), women with breast cancer (n=23), and representatives of associations (n=2). Additionally, 18 days of participant observation were conducted in a chemotherapy and palliative care departments in Cotonou, Benin. The data was analysed using Levesque et al.'s theoretical framework on access to healthcare.</p><p><strong>Results: </strong>Women encounter obstacles such as delayed diagnosis and unequal access to information, as well as socio-cultural beliefs that favour traditional medicine and discourage surgical interventions like mastectomy. The treatment pathway is often chaotic due to insufficient specialised caregivers and limited infrastructure, with services centralised in Cotonou forcing patients to travel long distances around the country. The current lack of radiotherapy requires patients in need to travel abroad for treatment. High costs of biomedical tests and treatments often lead to care abandonment, worsening health inequalities. However, positive changes should be highlighted, such as the establishment of the Inter-University Diploma in Gynaecological and Breast Oncology in 2013, the expansion of palliative care services in the country, and the planned opening of the Calavi International Hospital Centre in 2025. Challenges include continuing to train health professionals in oncology, further developing health financing and supporting civil society to raise awareness of breast cancer.</p><p><strong>Conclusions: </strong>Benin is facing several challenges in relation to the provision of timely and high-quality care for women with breast cancer. However, there is a growing commitment to enhancing breast cancer care in Benin.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"947"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.","authors":"Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-Xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu","doi":"10.1186/s12885-025-14223-8","DOIUrl":"10.1186/s12885-025-14223-8","url":null,"abstract":"<p><strong>Background: </strong>To investigate the treatment pattern, adverse events, and quality of life of Chinese patients treated with CDK4/6 inhibitors (CDK4/6i) for hormone receptor (HR)+/HER2- advanced breast cancer.</p><p><strong>Methods: </strong>This multicenter cross-sectional survey enrolled patients with HR+/HER2- advanced breast cancer currently treated with CDK4/6i. The patients reported adverse events and quality of life during CDK4/6i treatment with a questionnaire and EORTC QLQ-BR23. Meanwhile, the oncologists collected the treatment information, adverse events and patient characteristics from medical record.</p><p><strong>Results: </strong>The analysis included 1254 patients. Most patients received only one CDK4/6i, of which 38.92% received dalpiciclib, 35.81% received abemaciclib, 15.07% received palbociclib, and 0.47% received ribociclib, while 9.73% patients were treated with two CDK4/6i sequentially. The oncologists reported adverse events occurred in > 81.17% of patients, and most common AEs were leukopenia (63.30%) and neutropenia (58.73%). The most common symptomatic adverse events reported by the patients were fatigue (34.13%), alopecia (14.02%) and weakness (11.30%). The incidence of alopecia in patients receiving dalpiciclib was lower than in those receiving palbociclib (8.81% vs. 16.40%, P < 0.001) and abemaciclib (8.81% vs. 19.82%, P = 0.027). Regard to quality of life, breast symptom scores were lower in the palbociclib group than in the abemaciclib group (3.84 ± 8.57 vs. 5.70 ± 9.81, P = 0.047). Patient reported alopecia was associated with body image, systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss (all P < 0.001).</p><p><strong>Conclusions: </strong>The safety profile of different CDK4/6i varies and has different impacts on patients' quality of life, which needs more attention in clinical practice.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"951"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}